March 6, 2018 / 8:06 AM / 7 months ago

BRIEF-Biohaven Says Expects Topline Results From Phase 3 Trial With Rimegepant Zydis ODT In Q4​

March 6 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd:

* BIOHAVEN ENROLLS FIRST PATIENT IN PHASE 3 CLINICAL TRIAL TO EVALUATE RIMEGEPANT ZYDIS® ODT IN THE ACUTE TREATMENT OF MIGRAINE

* BIOHAVEN - CONTINUES TO EXPECT TOPLINE RESULTS FROM TWO PHASE 3 TRIALS EXAMINING EFFICACY OF RIMEGEPANT 75 MG ORAL TABLET VERSUS PLACEBO BY END OF Q1 2018​

* BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD SAYS ‍EXPECTS TOPLINE RESULTS FROM PHASE 3 TRIAL WITH RIMEGEPANT ZYDIS(®) ODT IN Q4 OF 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below